
Eli Lilly to buy Scorpion Therapeutics’ cancer therapy for up to $2.5 billion
(Reuters) -Eli Lilly said on Monday it plans to buy Scorpion Therapeutics’ experimental cancer therapy for up to $2.5 billion in cash to expand its pipeline of cancer treatments. The company will acquire Scorpion’s experimental oral therapy, STX-478, which is currently being tested in early-stage trials for breast cancer and other advanced solid tumors. The…